LUCD (Lucid Diagnostics) Marketable Securities: $0.00 Mil (As of Mar. 2026)


LUCD Lucid Diagnostics Inc LUCD
26 GF Score
Price $1.06
GF Value $0.81
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Marketable Securities?

Lucid Diagnostics LUCD -0.93% 26 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Lucid Diagnostics's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Lucid Diagnostics  (NAS:LUCD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Lucid Diagnostics Marketable Securities Related Terms

Lucid Diagnostics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Marketable Securities Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Lucid Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LUCD
26GF Score
Lucid Diagnostics Inc LUCD
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Lucid Diagnostics (LUCD) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Marketable Securities too high?
Lucid Diagnostics' current Marketable Securities is $0.00 Mil. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Marketable Securities compare to QTRX and INFU?
Lucid Diagnostics' Marketable Securities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.06 — trading 30.9% above its estimated fair value. The current Marketable Securities is $0.00 Mil. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.06 is trading 30.9% above its estimated GF Value™ of $0.81. GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.

Key valuation signals for LUCD:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $0.81 vs. price of $1.06 (30.9% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score

Get the complete analysis for LUCD

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.06
Price
$0.81
GF Value